Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.

A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus (HIV)-uninfected adults who were randomized to receive 10(6) or 10(7) TCID50 of canarypox (ALVAC) vector expressing HIV-1MN gp160 or 10(5.5) TCID50 of ALVAC-rabies virus glycoprotein control at 0 and 1 or 2 months and ALVAC-gp160 or 50 microg of HIV-1SF2 recombinant (r) gp120 in microfluidized emulsion at 9 and 12 months; others received rgp120 at 0, 1, 6, and 12 months. All vaccines were well-tolerated. Neither vaccinia-immune status before vaccination nor ALVAC dose affected HIV immune responses. HIV-1MN and HIV-1SF2 neutralizing antibodies were detected more often (100%) in ALVAC-gp160/rgp120 recipients than in recipients of ALVAC-gp160 (<65%) or rgp120 (89%) alone. ALVAC-gp160/rgp120 also elicited more frequent HIV V3-specific and fusion-inhibition antibodies, antibody-dependent cellular cytotoxicity, lymphoproliferation, and cytotoxic CD8+ T cell activity than did either vaccine alone. Trials with ALVAC expressing additional HIV components and rgp120 are underway.
AuthorsM L Clements-Mann, K Weinhold, T J Matthews, B S Graham, G J Gorse, M C Keefer, M J McElrath, R H Hsieh, J Mestecky, S Zolla-Pazner, J Mascola, D Schwartz, R Siliciano, L Corey, P F Wright, R Belshe, R Dolin, S Jackson, S Xu, P Fast, M C Walker, D Stablein, J L Excler, J Tartaglia, E Paoletti
JournalThe Journal of infectious diseases (J Infect Dis) Vol. 177 Issue 5 Pg. 1230-46 (May 1998) ISSN: 0022-1899 [Print] UNITED STATES
PMID9593008 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • AIDS Vaccines
  • ALVAC vaccine
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • Vaccines, Synthetic
  • Viral Vaccines
  • AIDS Vaccines (adverse effects)
  • Adult
  • Antibody Formation
  • Antibody-Dependent Cell Cytotoxicity
  • CD8-Positive T-Lymphocytes (immunology)
  • HIV Antibodies (biosynthesis, blood)
  • HIV Envelope Protein gp120 (adverse effects, immunology)
  • HIV-1 (immunology)
  • Humans
  • Immunization Schedule
  • Immunization, Secondary
  • Lymphocyte Activation
  • Lymphocytes (immunology)
  • Neutralization Tests
  • Rabies virus (immunology)
  • Time Factors
  • Vaccines, Synthetic (adverse effects)
  • Viral Vaccines (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: